Huntington Disease-Like 1 (HDL1) is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Huntington Disease-Like 1 (HDL1) is a rare autosomal dominant neurodegenerative disorder that clinically mimics Huntington's disease but is caused by mutations in the prion protein gene (PRNP). It is classified as a genetic prion disease and is characterized by a choreiform movement disorder, psychiatric disturbances, and progressive cognitive decline[1].
HDL1 is caused by an octapeptide repeat insertion mutation in the PRNP gene located on chromosome 20p13[^2]. The normal PRNP gene contains five octapeptide repeats (PHGGGWGQ), and HDL1 is associated with additional repeats (typically 7-9 repeats) that lead to abnormal prion protein (PrPSc) aggregation[^3].
| Feature | Details |
|---|---|
| Gene | PRNP (Prion Protein Gene) |
| Chromosome | 20p13 |
| Inheritance | Autosomal dominant |
| Mutation | Octapeptide repeat insertion (7-9 repeats) |
| Protein | Abnormal prion protein (PrPSc) |
The inserted repeats create a expanded polyglutamine-like sequence that promotes protein misfolding and aggregation, similar to the mechanism seen in Huntington's disease[^4].
Patients with HDL1 typically present in the third to fifth decade of life with a combination of:
Movement Disorders
Psychiatric Manifestations
Cognitive Decline
HDL1 follows a progressive course similar to Huntington's disease, with gradual worsening over 10-20 years. The average age of onset is typically between 30-50 years, with disease duration ranging from 5 to 20 years[^5].
The neuropathological features share characteristics with both Huntington's disease (striatal atrophy) and other prion diseases (spongiform change, PrP deposition)[^6].
HDL1 must be distinguished from:
| Condition | Key Differentiating Features |
|---|---|
| Huntington's disease | HTT gene CAG expansion, no PrP deposition |
| HDL2 (JPH3 mutation) | JPH3 gene mutation, African ancestry link |
| Other prion diseases | Specific clinical and pathological features |
| Spinocerebellar ataxias | Different genetic mutations, ataxia prominent |
| Wilson's disease | Copper metabolism abnormalities, Kayser-Fleischer rings |
Movement Disorders
Psychiatric Symptoms
Cognitive Symptoms
Currently, no disease-modifying therapies exist for HDL1. Experimental approaches include:
HDL1 is extremely rare, with only a few families reported worldwide. The prevalence is estimated at less than 1 in 1,000,000. Cases have been reported primarily in families of European descent[^8].
Transgenic mouse models carrying human PRNP with octapeptide repeat insertions have been developed and show features mimicking HDL1, including progressive neurological dysfunction and prion protein aggregation[^9].
Currently, no clinical trials are specifically targeting HDL1. Patients may be eligible for trials targeting other prion diseases or Huntington's disease symptomatic treatments.
This section highlights recent publications relevant to this disease.